A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas

Inclusion Criteria: * \- Page 3 of 4 \[DRAFT\] - Arms Assigned Interventions * Temodar Experimental: temozolomide +α-IFN Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN： 3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m\^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles Drug: Temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days Other Names: • Temodar Drug: α-IFN 3mIU (3million) D1，3，5 Other Names: Minimum Age: 18 Years Maximum Age: 75 Years Gender: Both Accepts Healthy Volunteers?: No Criteria: Inclusion Criteria: * Age: 18 years to 75 years * complete remission patients of newly diagnosed WHO III-IV glioma following standard treatment * Karnofsky Performance Score ≥ 60 * Adequate bone marrow, liver and renal function * Ability of subject to understand character and individual consequences of the clinical trial * Written informed consent * anticipating survival ≥2 months Exclusion Criteria: * Refusal to participate the study * Known hypersensitivity or contraindication to temozolomide * Incompletely radiation * Pregnant or lactating females * Malignant tumor other than brain tumor * Contraindicated for MRI examination * Unable to comply with the follow-up studies of this trial * Purulent and chronic infected wounds * Uncontrolled psychotic disorders or epilepsy * progression disease